CN101232888A - 用炔诺酮及其类似物治疗肌萎缩性侧索硬化 - Google Patents

用炔诺酮及其类似物治疗肌萎缩性侧索硬化 Download PDF

Info

Publication number
CN101232888A
CN101232888A CNA2006800153104A CN200680015310A CN101232888A CN 101232888 A CN101232888 A CN 101232888A CN A2006800153104 A CNA2006800153104 A CN A2006800153104A CN 200680015310 A CN200680015310 A CN 200680015310A CN 101232888 A CN101232888 A CN 101232888A
Authority
CN
China
Prior art keywords
sod
progesterone receptor
norethindrone
progesterone
als
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800153104A
Other languages
English (en)
Chinese (zh)
Inventor
S·斯科特
D·本杰明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ALSGEN Inc
Original Assignee
ALSGEN Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ALSGEN Inc filed Critical ALSGEN Inc
Publication of CN101232888A publication Critical patent/CN101232888A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CNA2006800153104A 2005-03-04 2006-03-01 用炔诺酮及其类似物治疗肌萎缩性侧索硬化 Pending CN101232888A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65863005P 2005-03-04 2005-03-04
US60/658,630 2005-03-04

Publications (1)

Publication Number Publication Date
CN101232888A true CN101232888A (zh) 2008-07-30

Family

ID=36825491

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800153104A Pending CN101232888A (zh) 2005-03-04 2006-03-01 用炔诺酮及其类似物治疗肌萎缩性侧索硬化

Country Status (7)

Country Link
US (2) US20060205704A1 (https=)
EP (1) EP1861107A2 (https=)
JP (1) JP2008536808A (https=)
CN (1) CN101232888A (https=)
AU (1) AU2006220918A1 (https=)
CA (1) CA2600064A1 (https=)
WO (1) WO2006096404A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060211645A1 (en) * 2005-03-04 2006-09-21 Alsgen, Llc Modulation of neurodegenerative diseases
US20100028360A1 (en) * 2008-07-26 2010-02-04 Craig Stephen Atwood Methods for the modulation of brain progestagen signaling in the prevention and treatment of neurological disorders and neurodegenerative diseases
EP2320912B1 (en) * 2008-08-05 2015-01-14 University College Cork-National University of Ireland, Cork Treatment of retinal degeneration
US9446051B2 (en) 2009-10-19 2016-09-20 The Population Council, Inc. Neuroprotection and myelin repair using nestorone®
WO2011049948A2 (en) * 2009-10-19 2011-04-28 The Population Council, Inc. Neuroprotection and myelin repair using nestorone®
CA2836388A1 (en) * 2012-12-21 2014-06-21 The Population Council, Inc. Neuroprotection and myelin repair using st-1435

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916910A (en) * 1997-06-04 1999-06-29 Medinox, Inc. Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore
US20050019915A1 (en) * 2001-06-21 2005-01-27 Bennett C. Frank Antisense modulation of superoxide dismutase 1, soluble expression
ATE433993T1 (de) * 2003-02-26 2009-07-15 Univ Johns Hopkins Modulatorische verbindungen und verfahren für glutamattransport
US20060211645A1 (en) * 2005-03-04 2006-09-21 Alsgen, Llc Modulation of neurodegenerative diseases

Also Published As

Publication number Publication date
AU2006220918A1 (en) 2006-09-14
JP2008536808A (ja) 2008-09-11
CA2600064A1 (en) 2006-09-14
EP1861107A2 (en) 2007-12-05
WO2006096404A3 (en) 2007-06-07
WO2006096404A2 (en) 2006-09-14
WO2006096404A8 (en) 2008-03-06
US20060205704A1 (en) 2006-09-14
US20090062245A1 (en) 2009-03-05

Similar Documents

Publication Publication Date Title
Gold et al. Estrogen treatment in multiple sclerosis
Li et al. Multi-system reproductive metabolic disorder: significance for the pathogenesis and therapy of polycystic ovary syndrome (PCOS)
Lan et al. Update on the neuroprotective effect of estrogen receptor alpha against Alzheimer's disease
Vagnerova et al. Gender and the injured brain
Hammond et al. Testosterone‐mediated neuroprotection through the androgen receptor in human primary neurons
Owen et al. RETRACTED: Maternal adversity, glucocorticoids and programming of neuroendocrine function and behaviour
Joshi et al. A novel therapeutic approach for treatment of catamenial epilepsy
Gilgun-Sherki et al. Riluzole suppresses experimental autoimmune encephalomyelitis: implications for the treatment of multiple sclerosis
KR20180043202A (ko) 암을 치료하는 방법
CN110891558A (zh) 使用芬氟拉明治疗多泽综合征的方法
JP2009102412A (ja) 糖質コルチコイドレセプター特異的アンタゴニストを使用するストレス障害を処置するための方法
Ancelin et al. Lifelong endocrine fluctuations and related cognitive disorders
US20090062245A1 (en) Modulation of Neurodegenerative Diseases Through The Progesterone Receptor
JP2003505336A (ja) 痴呆の処置のためのグルココルチコイドレセプターアンタゴニスト
Mancino et al. Tibolone restrains neuroinflammation in mouse experimental autoimmune encephalomyelitis
El-Lakany et al. Ovariectomy provokes inflammatory and cardiovascular effects of endotoxemia in rats: Dissimilar benefits of hormonal supplements
Alsadi Clinical features of PCOS
EP1917017B1 (en) Treatment of amyotrophic lateral sclerosis with pyrimethamine and analogues
Hu et al. Exogenous progesterone: a potential therapeutic candidate in CNS injury and neurodegeneration
Takemoto et al. An herbal medicine, Go-sha-jinki-gan (GJG), increases muscle weight in severe muscle dystrophy model mice
Kovanci et al. Polycystic ovary syndrome
US20060211673A1 (en) Modulation of neurodegenerative diseases through the estrogen receptor
WO2002087552A2 (en) Androgen-mediated neuroprotection and uses thereof
US10729693B2 (en) Compositions and methods for the treatment of endometriosis
EP1386615A1 (de) EG-VEGF/Prokineticin 2 Rezeptor Antagonisten

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20080730